ReviewEuropean respiratory review : an official journal of the European Respiratory Society2024
Infection and the microbiome in bronchiectasis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bronchiectasis in children: a systematic review of cytokine profile, immune cell phenotypes and microbiota in bronchoalveolar lavage fluid.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- The frequent exacerbator phenotype in bronchiectasis revisited: data from EMBARC registry.American journal of respiratory and critical care medicine · 2026Article
- Beyond Pathogens: Modulating the Commensal Microbiota to Reshape Immunity for Respiratory Disease Intervention.Pathogens (Basel, Switzerland) · 2026Review
- Differential analysis of the lower respiratory tract microbiota between patients with non-tuberculous mycobacterial pulmonary disease and pulmonary tuberculosis.BMC microbiology · 2026Article
- The respiratory microbiome: dynamics from health to disease.FEMS microbiology ecology · 2026Review
- Review
- Targeting Inflammation in Bronchiectasis.Drugs · 2026Review
- Low levels of IgG2 and pneumococcal antibodies as predictors of benefit from IgG replacement in IgG subclass deficiency.Journal of human immunity · 2026Article
- Bronchiectasis in the precision medicine era: pathogenesis and therapeutic advances.Journal of thoracic disease · 2026Review
- Single-bacterial cell insights into mechanisms of ceftriaxone resistance in Neisseria subflava.Nature communications · 2026Article
- Review
- Fungal-Associated Endotypes as a Treatable Trait in Bronchiectasis.Pulmonary therapy · 2026Review
- Clinical and prognostic characteristics of stable bronchiectasis in adults with chronic Pseudomonas aeruginosa infection: a prospective cohort study.BMC pulmonary medicine · 2026Article
- Risk factors and prediction model for chronic bacterial infection in stable bronchiectasis in Shanghai, China.Frontiers in medicine · 2026Article
- Gut-Lung Axis Microbiome Dysbiosis and Cross-Domain Network Analysis in Bronchiectasis Complicated by Invasive Pulmonary Aspergillosis.Infection and drug resistance · 2026Article
- Allergic bronchopulmonary aspergillosis andJournal of thoracic disease · 2025Review
- Characterising research trends in bronchiectasis through AI-powered analytics.The European respiratory journal · 2025Review
- Exploring the molecular mechanism of apigenin in treating bronchiectasis based on network pharmacology and molecular docking.Scientific reports · 2025Article
- Pseudomonas aeruginosa-driven airway dysbiosis and machine learning prediction of acute exacerbations in non-cystic fibrosis bronchiectasis: a microbial-inflammatory signature approach.BMC pulmonary medicine · 2025Article
- Respiratory Microbiota Associations with Asthma Across American and Emirati Adults: A Comparative Analysis.Applied microbiology (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is marked by bronchial dilatation, recurrent infections and significant morbidity, underpinned by a complex interplay between microbial dysbiosis and immune dysregulation. The identification of distinct endophenotypes have refined our understanding of its pathogenesis, including its heterogeneous disease mechanisms that influence treatment and prognosis responses. Next-generation sequencing (NGS) has revolutionised the way we view airway microbiology, allowing insights into the "unculturable". Understanding the bronchiectasis microbiome through targeted amplicon sequencing and/or shotgun metagenomics has provided key information on the interplay of the microbiome and host immunity, a central feature of disease progression. The rapid increase in translational and clinical studies in bronchiectasis now provides scope for the application of precision medicine and a better understanding of the efficacy of interventions aimed at restoring microbial balance and/or modulating immune responses. Holistic integration of these insights is driving an evolving paradigm shift in our understanding of bronchiectasis, which includes the critical role of the microbiome and its unique interplay with clinical, inflammatory, immunological and metabolic factors. Here, we review the current state of infection and the microbiome in bronchiectasis and provide views on the future directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.